Ann Pediatr Endocrinol Metab.  2015 Mar;20(1):21-26. 10.6065/apem.2015.20.1.21.

Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus

• Kang DS
• Park J
• Kim JK
• Yu J

• KMID: 1789527
• DOI: http://doi.org/10.6065/apem.2015.20.1.21

Abstract

PURPOSE
Glycosylated hemoglobin (HbA1c) is often used as an indicator of glucose control. It usually reflects the average glucose levels over two to three months, and is correlated with the development of long-term diabetic complications. However, it can vary in cases of hemoglobinopathy or an altered red blood cell lifespan. The serum fructosamine levels reflect the mean glucose levels over two to three weeks. This study was designed to determine the clinical usefulness of the combined measurement of serum fructosamine and HbA1c in the management of childhood diabetes mellitus and the correlation between them.
METHODS
Clinical data on 74 Korean children and adolescents with diabetes mellitus who were under management at the Department of Pediatrics of Dankook University Hospital were evaluated. Their fructosamine and HbA1c levels were reviewed based on clinical information, and analyzed using IBM SPSS Statistics ver. 21.
RESULTS
Their HbA1c levels showed a strong correlation with their fructosamine levels (r=0.868, P<0.001). The fructosamine level was useful for the prompt evaluation of the recent therapeutic efficacy after the change in therapeutic modality. It was also profitable in determining the initial therapeutics and for the estimation of the onset of the disease, such as fulminant diabetes.
CONCLUSION
The measurement of both fructosamine and HbA1c was useful in managing childhood diabetes mellitus, especially when there was discrepancy between the clinical information and the HbA1c level.

Keyword

Fructosamine; Glycosylated hemoglobin A; Diabetes mellitus; Child

MeSH Terms

Adolescent
Child
Diabetes Complications
Diabetes Mellitus*
Erythrocytes
Fructosamine*
Glucose
Hemoglobin A, Glycosylated
Hemoglobinopathies
Humans
Pediatrics
Fructosamine
Glucose
Hemoglobin A, Glycosylated

Figure

• 

  Fig. 1 Correlation between serum fructosamine and plasma glycosylated hemoglobin (HbA1c) in children and adolescents with diabetes mellitus. y=48.55x-45.84. r2=0.753.

Reference

1. Alemzadeh R, Ali O. Diabetes mellitus in children. In : Kliegman RM, Stanton BF, St. Geme JW, Schor NF, Behrman RE, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Elsevier Saunders;2011. p. 1968–1997.

2. Haemoglobin A1 and diabetes; a reappraisal. Br Med J. 1980; 281:1304–1305. PMID: 7437773.

3. Graf RJ, Halter JB, Porte D Jr. Glycosylated hemoglobin in normal subjects and subjects with maturity-onset diabetes. Evidence for a saturable system in man. Diabetes. 1978; 27:834–839. PMID: 680410.

4. Boden G, Master RW, Gordon SS, Shuman CR, Owen OE. Monitoring metabolic control in diabetic outpatients with glycosylated hemoglobin. Ann Intern Med. 1980; 92:357–360. PMID: 7356230.

5. Kennedy AL, Merimee TJ. Glycosylated serum protein and hemoglobin A1 levels to measure control of glycemia. Ann Intern Med. 1981; 95:56–58. PMID: 7247128.

6. Baker JR, O'Connor JP, Metcalf PA, Lawson MR, Johnson RN. Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. Br Med J (Clin Res Ed). 1983; 287:863–867.

7. Chen HS, Wu TE, Lin HD, Jap TS, Hsiao LC, Lee SH, et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. 2010; 55:867–874. PMID: 20202728.

8. Shafi T, Sozio SM, Plantinga LC, Jaar BG, Kim ET, Parekh RS, et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care. 2013; 36:1522–1533. PMID: 23250799.

9. Chon S, Lee YJ, Fraterrigo G, Pozzilli P, Choi MC, Kwon MK, et al. Evaluation of glycemic variability in wellcontrolled type 2 diabetes mellitus. Diabetes Technol Ther. 2013; 15:455–460. PMID: 23617251.

10. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008; 31:1473–1478. PMID: 18540046.

11. Desrocher M, Rovet J. Neurocognitive correlates of type 1 diabetes mellitus in childhood. Child Neuropsychol. 2004; 10:36–52. PMID: 14977514.

12. Daneman D, Frank M, Perlman K, Tamm J, Ehrlich R. Severe hypoglycemia in children with insulin-dependent diabetes mellitus: frequency and predisposing factors. J Pediatr. 1989; 115(5 Pt 1):681–685. PMID: 2491424.

13. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child. 1998; 78:111–115. PMID: 9579150.

14. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2003; 26:163–167. PMID: 12502674.

15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977–986. PMID: 8366922.

16. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103–117. PMID: 7587918.

17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–853. PMID: 9742976.

18. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care. 2011; 34:518–523. PMID: 21270207.

19. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? Diabetologia. 2009; 52:1279–1289. PMID: 19387611.

20. Wright LA, Hirsch IB. The challenge of the use of glycemic biomarkers in diabetes: reflecting on hemoglobin A1C, 1,5-Anhydroglucitol, and the glycated proteins fructosamine and glycated albumin. Diabetes Spectrum. 2012; 25:141–148.

21. Panzer S, Kronik G, Lechner K, Bettelheim P, Neumann E, Dudczak R. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood. 1982; 59:1348–1350. PMID: 7082831.

22. Shapira Y, Vaturi M, Sagie A. Hemolysis associated with prosthetic heart valves: a review. Cardiol Rev. 2009; 17:121–124. PMID: 19384085.

23. Jain N, Kesimer M, Hoyer JD, Calikoglu AS. Hemoglobin Raleigh results in factitiously low hemoglobin A1c when evaluated via immunoassay analyzer. J Diabetes Complications. 2011; 25:14–18. PMID: 19896869.

24. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001; 47:153–163. PMID: 11159762.

25. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35:134–148. PMID: 2651751.

26. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004; 44:715–719. PMID: 15384023.

27. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care. 2003; 26:2728–2733. PMID: 14514571.

28. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005; 54:1–7. PMID: 15616004.

29. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose f luc tuat ions compared with sus t ained chroni c hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295:1681–1687. PMID: 16609090.

30. Juraschek SP, Steffes MW, Miller ER 3rd, Selvin E. Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care. 2012; 35:2265–2270. PMID: 22875225.

31. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011; 93:645–658. PMID: 21167901.

32. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther. 2003; 5:355–363. PMID: 12828817.

33. Rubinow KB, Hirsch IB. Reexamining metrics for glucose control. JAMA. 2011; 305:1132–1133. PMID: 21406652.

34. Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int. 2010; 30:72–79. PMID: 20056983.

35. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008; 73:1062–1068. PMID: 18288102.

36. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007; 18:896–903. PMID: 17267743.

37. True MW. Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol. 2009; 3:743–747. PMID: 20144323.

38. Baker JR, Johnson RN, Scott DJ. Serum fructosamine concentrations in patients with type II (non-insulindependent) diabetes mellitus during changes in management. Br Med J (Clin Res Ed). 1984; 288:1484–1486.

39. Tattersall R, Walford S, Peacock I, Gale E, Allison S. A critical evaluation of methods of monitoring diabetic control. Diabetes Care. 1980; 3:150–154. PMID: 7408605.

40. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007; 3:36–45. PMID: 17179928.